MEN1 vs MEN2
How to tell MEN1 and MEN2 apart when a board question makes them look alike.
MEN1 is MEN1 gene with the three P tumors; MEN2 is RET with medullary thyroid carcinoma and pheochromocytoma.
Side by side
MEN1 gene pattern with parathyroid, pituitary, and pancreatic endocrine tumors: the classic three-P pattern.
RET pattern with medullary thyroid carcinoma and pheochromocytoma; MEN2A adds parathyroid disease and MEN2B adds mucosal neuromas/marfanoid habitus.
MEN1 tumor suppressor mutation drives endocrine tumors.
RET proto-oncogene activation drives MEN2 syndromes.
MEN1 (MEN1 gene mutation, autosomal dominant): primary hyperparathyroidism with high PTH and high calcium, pancreatic neuroendocrine tumor markers (high gastrin and refractory ulcers for gastrinoma, hypoglycemia with high insulin and C-peptide for insulinoma), pituitary adenoma (high prolactin for prolactinoma, high IGF-1 for acromegaly).
MEN2 (RET proto-oncogene): elevated calcitonin in medullary thyroid carcinoma (amyloid deposits from calcitonin precursor on biopsy), elevated plasma free metanephrines in pheochromocytoma, elevated PTH and calcium in 2A only. MEN2B adds mucosal neuromas on lips and tongue plus marfanoid body habitus. Prophylactic thyroidectomy is recommended in childhood for MEN2 family members with positive RET screening.
The trap
Both MEN syndromes include parathyroid disease, so primary hyperparathyroidism alone does not pick the syndrome. The anchor tumor decides. MEN1 (Wermer syndrome, MEN1 gene, autosomal dominant) is the 3 P's: Parathyroid hyperplasia, Pancreatic neuroendocrine tumors (gastrinoma is the most common functional type, also insulinoma), Pituitary adenoma (prolactinoma most common). MEN2A (Sipple syndrome, RET proto-oncogene gain-of-function) is Parathyroid hyperplasia plus Medullary thyroid carcinoma (with elevated calcitonin and amyloid deposits) plus Pheochromocytoma. MEN2B is medullary thyroid carcinoma + pheochromocytoma + mucosal neuromas + marfanoid habitus (NO parathyroid disease). Anyone with confirmed medullary thyroid carcinoma needs genetic testing for RET and prophylactic thyroidectomy in family members.
Watch it explained
The repair move
Use the anchor tumor and gene pattern: pancreatic NET points MEN1; medullary thyroid carcinoma/calcitonin or pheo points RET/MEN2.
Try a free question
CoreA patient has hyperparathyroidism, a pancreatic endocrine tumor, and a pituitary adenoma. Which inherited syndrome best fits?
Show answer and explanation
Answer: A. MEN1. MEN1 is the three Ps: parathyroid, pituitary, and pancreatic endocrine tumors.
Why the other choices are tempting
- B. MEN2 centers on medullary thyroid carcinoma and pheochromocytoma.
- C. VHL causes hemangioblastomas, RCC, pheochromocytoma, and other tumors.
- D. NF1 causes cafe-au-lait macules and neurofibromas.
- E. Tuberous sclerosis causes hamartomas, seizures, and skin findings.
Flashcards
Tap a card to flip it.
What is the fastest separator for MEN1 vs MEN2?
MEN1 is MEN1 gene with the three P tumors; MEN2 is RET with medullary thyroid carcinoma and pheochromocytoma.
What clue should make you choose MEN1?
MEN1 gene pattern with parathyroid, pituitary, and pancreatic endocrine tumors: the classic three-P pattern.
Quick answers
What is the fastest way to tell MEN1 from MEN2?
MEN1 is MEN1 gene with the three P tumors; MEN2 is RET with medullary thyroid carcinoma and pheochromocytoma.
What is the key clue for MEN1?
MEN1 gene pattern with parathyroid, pituitary, and pancreatic endocrine tumors: the classic three-P pattern.
What is the key clue for MEN2?
RET pattern with medullary thyroid carcinoma and pheochromocytoma; MEN2A adds parathyroid disease and MEN2B adds mucosal neuromas/marfanoid habitus.
What is the common trap with MEN1 vs MEN2?
Both MEN syndromes include parathyroid disease, so primary hyperparathyroidism alone does not pick the syndrome. The anchor tumor decides. MEN1 (Wermer syndrome, MEN1 gene, autosomal dominant) is the 3 P's: Parathyroid hyperplasia, Pancreatic neuroendocrine tumors (gastrinoma is the most common functional type, also insulinoma), Pituitary adenoma (prolactinoma most common). MEN2A (Sipple syndrome, RET proto-oncogene gain-of-function) is Parathyroid hyperplasia plus Medullary thyroid carcinoma (with elevated calcitonin and amyloid deposits) plus Pheochromocytoma. MEN2B is medullary thyroid carcinoma + pheochromocytoma + mucosal neuromas + marfanoid habitus (NO parathyroid disease). Anyone with confirmed medullary thyroid carcinoma needs genetic testing for RET and prophylactic thyroidectomy in family members.